Home

Βρίσκεστε εδώ : Βιβλιογραφία

• COVID-19 vaccines and kidney disease
  
• COVID-19- associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup (NATURE REVIEWS | NEPHROLOGY, CONSENSUS Statement, volume 16 | December 2020)
• Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19 (Clinica Chimica Acta 509 (2020) 220–223, doi.org: 10.1016/j.cca.2020.06.026)
• Perspective Piece All together to Fight COVID-19 (Am. J. Trop. Med. Hyg., 102(6), 2020, pp. 1181–1183, doi:10.4269/ajtmh.20-0281)
• Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs During the Early Phase of the COVID-19 Pandemic in Italy (JAMA Network Open. 2021;4(2):e2037060. doi:10.1001/jamanetworkopen.2020.37060)
• COVID-19 and the Kidney Community: Coalescing in Crisis (Adv Chronic Kidney Dis. 2020;27(5):362-364, doi: 10.1053/j.ackd.2020.10.001)
• Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More (JAMA Published online February 10, 2021)
• Researchers Investigate What COVID-19 Does to the Heart (JAMA Published online February 10, 2021)
• COVID-19 Vaccination in Pregnant and Lactating Women (JAMA Published online February 8, 2021)
• Effectiveness of MaskWearing to Control Community Spread of SARS-CoV-2 (JAMA Published online February 10, 2021)
• Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection (JAMA Published online January 26, 2021)
• Necessity of 2 Doses of the Pfizer andModerna COVID-19 Vaccines (JAMA Published online February 3, 2021)
• Monoclonal Antibodies for COVID-19 (JAMA Published online February 5, 2021)
• Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. A Randomized Clinical Trial (JAMA. 2021;325(3):254-264. doi:10.1001/jama.2020.25864)
• A Viral Pandemic, Vaccine Safety, and Compensation for Adverse Events (JAMA Published online February 5, 2021)
• SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants (JAMA Published online January 28, 2021)
• Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk (JAMA January 26, 2021 Volume 325, Number 4)
• Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 (JAMA Published online February 12, 2021)
• Emergence of a Novel SARS-CoV-2 Variant in Southern California (JAMA Published online February 11, 2021)
• Outpatient Dietary Management of Electrolyte Disorders During COVID-19 (JAMA Internal Medicine Published online February 8, 2021)
• SARS-CoV-2 Transmission From People Without COVID-19 Symptoms (JAMA Network Open. 2021;4(1):e2035057. doi:10.1001/jamanetworkopen.2020.35057)
• Food as medicine: A possible preventive measure against coronavirus disease (COVID-19) (Phytotherapy Research. 2020;34:3124–3136)
• Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection. The COVID A to Z Randomized Clinical Trial (JAMA Network Open. 2021;4(2):e210369. doi:10.1001/jamanetworkopen.2021.0369)
  
• Estimation of US Children’s Educational Attainment and Years of Life Lost Associated With Primary School Closures During the Coronavirus Disease 2019 Pandemic (JAMA Network Open. 2020;3(11):e2028786. doi:10.1001/jamanetworkopen.2020.28786)
  
• COVID-19 and mRNA Vaccines—First Large Test for a NewApproach (JAMA September 22/29, 2020 Volume 324, Number 12)
  
• Relationships Between AcademicMedicine Leaders and Industry—Time for Another Look? (JAMA November 10, 2020 Volume 324, Number 18)
  
• Therapy for Early COVID-19 A Critical Need (JAMA Published online November 11, 2020)
  
• Risk of COVID-19 During Air Travel (JAMA November 3, 2020 Volume 324, Number 17)
  
• COVID-19 Infection—Preventing Clinical Deterioration (JAMA Published online November 12, 2020)
  
• COVID-19 of dialysis patients in Japan: current status and guidance on preventive measures
  
• Coronavirus Disease 2019 (COVID-19) and Dialysis: The Experience in Singapore
  
• Managing the COVID-19 pandemic: international comparisons in dialysis patients
  
• Hemodialysis with Cohort Isolation to Prevent Secondary Transmission during a COVID-19 Outbreak in Korea
  
• COVID-19 and the Kidney: From Epidemiology to Clinical Practice
  
• Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). A Review
  
• Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea
  
• A brand-new cardiorenal syndrome in the COVID-19 setting
  
• Kidney disease and electrolytes in COVID-19: more than meets the eye
  
• Epidemiology of COVID-19 in an Urban Dialysis Center
  
• Maintenance Hemodialysis and COVID-19: Saving Lives With Caution, Care, and Courage
  
• Coronavirus disease 2019 in chronic kidney disease
  
• Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
  
• The clinical characteristics of coronavirus-associated nephropathy
  
• First considerations on the SARS‑CoV‑2 epidemic in the Dialysis Units of Piedmont and Aosta Valley, Northern Italy
  
• Presence of Genetic Variants Among Young Men With Severe COVID-19
  
• Delivering Dialysis During the COVID-19 Outbreak: Strategies and Outcomes
  
• Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID‑19 pandemic: survey of the Italian Society of Nephrology
  
• Serosurveillance and the COVID-19 Epidemic in the US Undetected, Uncertain, and Out of Control
  
• Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities
  
• A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece
  
• Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities
  
• COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
  
• The psychological impact of quarantine and how to reduce it: rapid review of the evidence
  
• COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
  
• Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health CareWorkers
  
• Minimizing the risk of COVID-19 among patients on dialysis
  
• COVID-19 Town Hall WEBINAR Registration Detail
• Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19
• PRESYMPTOMATIC TRASMISSION OF SARS- COV2
• HD PTS WITH COVID-19
• COVID experience in Lombardy, Italy
• Management of kidney transplant immunosuppression LaPaz
• ERA-EDTA sharing Milano experience on coronavirus management in dialysis centers
• DIALYSIS COVID 2019 (Update)
• Dialysis Facilities Brace for COVID-19 - Renal and Urology News
• ERA-EDTA news and informations
• CDC
• 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China
• Άρθρο NDT για την μείωση της διασποράς του COVID – 19 στην αιμοκάθαρση από το EUDIAL Working Group of ERA-EDTA
• Watch the COVID-19 Organ Donation and Transplant Town Hall
• WEBINAR «Infection Prevention and Control in the time of Covid-19».
• Your invitation to the COVID-19 Town Hall Webinar